Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/4/2010

rresponding periods of 2009. The increases in 2010 were due mainly to higher employee expenses including severance charges, professional fees for legal and accounting services, employee recruitment costs and stock based compensation expense.

In September 2010, we revised our sublease income assumptions used to estimate the excess lease facility liability associated with our office space located in Bothell, Washington. This change in estimate resulted in an increase of the excess lease liability and $4.0 million in restructuring expense recorded in September 2010. This is a non-cash item and does not impact the Company's cash flow projections going forward. The estimated liability remaining with respect to excess facilities was $7.8 million as of September 30, 2010.

The net loss for the third quarter was $6.9 million compared to a $2.4 million net loss in the same period 2009. This increase is primarily due to the non-cash restructuring expense related to our facilities lease. For the nine months ended September 30, 2010 the net loss increased to $9.8 million from $9.4 million in 2009.

The Company had $42.1 million in cash and investment securities as of September 30, 2010, compared to $64.6 million at December 31, 2009. Together with the estimated $46.7 million net proceeds from the public offering completed in October 2010, we anticipate ending the year with cash, cash equivalents, short-term investments, and amounts receivable of between $83 million and $85 million.

The Company had 9,658,591 shares outstanding as of November 4, 2010.  Conference Call Today at 4:30 p.m. ET 
OncoGenex management will host a conference call at 4:30 p.m. Eastern Time today to provide a business update and discuss the third quarter results. A live webcast will be available through the Events and Presentations Web page found in the Investor Relations section of the OncoGenex Web site at www.ir.o
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
2. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
3. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
4. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
5. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
6. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
7. OncoGenex Reports Second Quarter Financial Results
8. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
9. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
10. OncoGenex Reports First Quarter Financial Results
11. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Toronto, Canada (PRWEB) August 22, 2014 ... traits in model organisms can be accelerated by ... design and manufacturing technologies, the custom SeqCap EZ ... such research. , Mr. Watson will additionally present ... seen with commercially available human and mouse exome ...
(Date:8/21/2014)... LYNBROOK, N.Y. , Aug. 21, 2014 /PRNewswire/ ... a biopharmaceutical company developing first in class collagenase-based ... histolyticum or CCH) in the U.S. and XIAPEX ... statistically significant results from a randomized, double-blind Phase ... of cellulite, or edematous fibrosclerotic panniculopathy. The results ...
(Date:8/21/2014)... Finnish-Swedish research group at the Institute for Molecular ... institutet, Stockholm, has developed a novel "man and ... This innovative diagnostic aid was described in ... The method is based on computer vision algorithms ... combined with visualization of only the diagnostically most ...
(Date:8/21/2014)... August 21, 2014 2014 ... Industryā€¯ is a professional and in-depth research ... report provides basic Seaweed Fertilizer information, including ... chain structure as well as industry overview. ... including domestic market as well as global ...
Breaking Biology Technology:Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3
... Biomedical, Inc., a privately held company developing and commercializing ... medicine for new and existing therapeutics, announced today that ... has been elected as chairman for the company,s board ... certified pathologist with more than 20 years experience in ...
... Rosetta Genomics, Ltd. (NASDAQ: ... molecular diagnostic tests, today announced the effectiveness of a ... reverse stock split, which was previously approved by the ... at the 2011 Annual General Meeting of Shareholders of ...
... the Universities of East Anglia, York and Nottingham and using ... hair, the researchers are working on harnessing the vast energy ... are presenting their research at the Royal Society,s annual Summer ... Members of the consortium at UEA have already found ...
Cached Biology Technology:Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Company's Board of Directors 2Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Company's Board of Directors 3Rosetta Genomics Announces One-For-Four Reverse Stock Split 2Rosetta Genomics Announces One-For-Four Reverse Stock Split 3Rosetta Genomics Announces One-For-Four Reverse Stock Split 4Putting sunshine in the tank 2
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ... it has agreed to a partnership with Gabriel ... fastest growing Certified Nursing Assistant ... Health Institute  an exclusive member of Binary,s LiveScan ... Binary Biometrics will improve its service capabilities ...
(Date:8/21/2014)... Nine researchers from Beth Israel Deaconess Medical ... "The World,s Most Influential Scientific Minds 2014," ... Reuters ScienceWatch, a web resource for science metrics and ... as among the most influential "are performing and publishing ... advancement of their science," according to a Thomson Reuters ...
(Date:8/21/2014)... a key region in the global oceanic circulation. "On the ... Atlantic water flows to the north into the Arctic Ocean ... sea ice push their way out of the Arctic into ... cools here on its way to the north and sinks ... this manner drives the global band of oceanic currents like ...
Breaking Biology News(10 mins):LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3
... -- Scientists at Weill Cornell Medical College have taken an ... uncovering evidence that it is not one disease, as previously ... in the future, destroyed by targeted therapy., ... Mark A. Rubin, the Homer T. Hirst Professor of Oncology ...
... are just some of the biological topics to which ... Mathematical and Biological Synthesis (NIMBioS) will host a tutorial ... models with an emphasis on biological applications. ... outcomes in order to predict what conditions might be ...
... Scientists are reporting the development of a simple, built-in ... and test strips for diagnosing diseases inexpensively at-home and ... Analytical Chemistry . Scott Phillips and Hyeran ... tests and others performed at home or bedside instead ...
Cached Biology News:Prostate cancer's multiple personalities revealed 2Tutorial addresses stochastic modeling in biological process 2Built-in timer for improving accuracy of cost saving paper-strip medical tests 2
... Simultaneously perform 96 assays on four ... four microarray slides with 96 (6mm x ... protein, gene expression, or screening analysis studies. ... compression fit gasket, eliminating the presence of ...
... is an automated multiplexing platform that uses ... pathogen sequence detection and pharmacogenetics applications. Multiple ... to an open and flexible electronic microarray, ... until all tests sites have been utilized. ...
... with sequence siTrio siRNA --- a ... target gene of interestis our most popular product. ... 75% knockdown of your target gene when used ... and confirmation of optimal transfection with one of ...
The Bio-Plex Manager version 3.0 to 4.0 workstation software upgrade kit is used to upgrade existing Bio-Plex Manager version 3.0 software to version 4.0 security edition software....
Biology Products: